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Abstract
We aimed to investigate whether periconceptional maternal folate status affects human
embryonic cerebellar size and growth trajectories. In a prospective periconceptional cohort
participants filled out questionnaires and received weekly transvaginal 3D-ultrasounds
between 7+0 and 12+6 weeks gestational age (GA). Viable non-malformed singleton preg-
nancies were selected for cerebellar measurements; transcerebellar diameter, (TCD), left
and right cerebellar diameters (LCD, RCD). Linear mixed models were performed to esti-
mate associations between questionnaire data on the timing of maternal folic acid supple-
ment initiation and longitudinal cerebellar measurements as a function of crown-rump
length (CRL) and GA. Maternal red blood cell folate concentrations were analysed before 8
weeks GA to validate the associations. A total of 263 serial high quality three-dimensional
ultrasound scans of 135 pregnancies were studied. Preconceptional compared to postcon-
ceptional initiation of folic acid use was associated with slightly larger cerebellar diameters
per millimetre increase of CRL (TCD: β = 0.260mm, 95%CI = 0.023–0.491, p<0.05; LCD:
β = 0.171mm, 95%CI = 0.038–0.305, p<0.05; RCD: β = 0.156mm, 95%CI = 0.032–0.280,
p<0.05) and with proportional cerebellar growth (TCD/CRL:β = 0.015mm/mm, 95%CI =
0.005–0.024, p<0.01; LCD/CRL:β = 0.012mm/mm, 95%CI = 0.005–0.018, p<0.01; RCD/
CRL:β = 0.011mm/mm, 95%CI = 0.005–0.017, p<0.01). Cerebellar growth was significantly
highest in the third quartile of maternal red blood cell folate levels (1538–1813 nmol/L).
These first findings show that periconceptional maternal folate status is associated with
human embryonic cerebellar development. Implications of these small but significant varia-
tions for fetal cerebellar growth trajectories and the child’s neurodevelopmental outcome
are yet unknown and warrant further investigation.
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Introduction
Last decades our understanding of the complex functions of the human cerebellum has
expanded immensely. Previous literature demonstrated cerebellar involvement in motor and
non-motor functions including perception, cognition and emotion [1,2]. Yet, prenatal studies
of the cerebellum have mainly been focussing on abnormal cerebellar development and mor-
phology in the second half of pregnancy when ultrasonography landmarks of development can
be visualized [3–5]. However, the first trimester of pregnancy is known to be essential for
organogenesis and deviations in growth and development are likely to originate during this
particular period. Nowadays, ultrasound measurements of embryonic structures are more eas-
ily accessible through the improvements of ultrasound techniques. Growth charts of embryonic
brain structures including the cerebellum were created with measurements performed between
7+0 and 12+6 weeks of gestation using three-dimensional ultrasound and virtual reality ultra-
sound visualization [6]. Three-dimensional techniques provide very precise information on
variations in first trimester cerebellar growth trajectories.
Development of the cerebellum starts from the 6th week of gestation and extends to the first
years of life [7]. Due to this protracted process, the cerebellum is extremely vulnerable to dis-
turbances in its development caused by a complex interplay of genetic and environmental fac-
tors [8,9]. Perinatal environmental and genetic risk factors act at particular time windows
when cerebellar development is most vulnerable to derangements [10]. Maternal exposures
and conditions during the periconceptional period are known to influence embryonic growth
[11–13]. These factors may also affect embryonic cerebellar growth with potential implications
for fetal cerebellar growth and neurodevelopmental functions in later life [14,15].
Periconceptional maternal folate status plays a vital role in biological processes involved in
cellular growth and differentiation [16]. Maternal folate deficiency is associated with a broad
spectrum of reproductive failures [17]. In addition, maternal periconceptional folic acid sup-
plement use is known to reduce the risk of congenital anomalies such as neural tube defects
and probably also congenital heart disease and oral facial clefts and offspring born small for
gestational age (SGA) [18–20]. Furthermore adequate maternal periconceptional folic acid use
seems beneficial to early and late human neurodevelopmental outcome and may reduce the
risk of neurodevelopmental disorders including autism spectrum disorder in which the cerebel-
lum seems to play a key role [21–26]. Animal models show dramatic alterations in both prena-
tal and postnatal cerebellar growth and development when derangements of the folate pathway
and changes in folate status occurred [27,28]. So far no human studies reported on conse-
quences of maternal folic acid supplement use on the growth and development of the human
cerebellum. From this perspective we aim to investigate whether the timing of maternal folic
acid supplement initiation during the periconceptional period as measure of periconceptional
maternal folate status affects human embryonic cerebellar size and growth trajectories in preg-
nancies ending in live births without congenital malformations.
Materials and Methods
Study Population
This study is embedded in the Rotterdam Predict study, an ongoing prospective periconcep-
tional cohort investigating the influence of gene-environment interactions and underlying
mechanisms on reproductive, (extra-)embryonic and pregnancy outcome at the Erasmus MC
University Medical Centre, Rotterdam, The Netherlands [13]. Pregnant women of at least 18
years of age with a gestational age (GA) of less than 8 weeks were eligible for participation and
were followed until 1 year after delivery. All pregnant women and their partners gave written
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informed consent before participation. The Central Committee of Human Research in The
Hague and the regional Medical Ethical and Institutional Review Board of the Erasmus MC
University Medical Centre approved the study (MEC 2004–227, 15 October 2004).
We selected singleton pregnancies conceived spontaneously or through assisted reproduc-
tive techniques using biological oocytes from the participating mother with reliable GA only.
GA was defined as reliable when; 1) GA was calculated using the first day of the last menstrual
period (LMP) confirmed by first trimester ultrasound evaluation for spontaneously conceived
pregnancies with regular menstrual cycles of approximately 28 days and was adjusted when the
cycle was prolonged (>31 days) or shortened (<25 days). 2) In pregnancies assisted with in
vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI) and intra-uterine insemina-
tion, GA was calculated from the date of oocyte retrieval plus 14 days, from the day of embryo
transfer plus 17 or 18 days cryopreserved embryo transfers, or from insemination date plus 14
days respectively.
In our statistical analyses, we used Crown-rump Length (CRL) as outcome variable. There-
fore when there was no reliable recall of the (LMP) or CRL measurements differed more than 7
days from the expected GA, pregnancies were dated on CRL and consequently excluded.
Because this study aimed to investigate the initiation of periconceptional maternal folic acid
supplement intake in pregnancies ending in live births without congenital malformations, we
also excluded pregnancies ending in miscarriages, ectopic pregnancy and termination of preg-
nancy or pregnancies with adverse foetal outcome including minor and major congenital mal-
formations, foetal or neonatal death. When data from questionnaires or maternal folic acid
status was missing, pregnancies were also excluded from further analysis.
Measurements
The study visit before 8 weeks GA was used to verify self-administered questionnaires to obtain
information on the current pregnancy with regard to maternal age, preconceptional weight
and height, ethnicity, educational level, medical history, gynaecological and obstetric history,
familial hereditary or congenital disorders and diseases, diet, lifestyle and the use of folic acid
and/or other (multi)vitamin supplements. The accuracy of the self-reported questionnaires
was enhanced by an intake consultation at enrolment discussing unclear topics and questions.
Follow-up on pregnancy, fetal and infant outcomes comprised of questionnaires validated by
the structural ultrasound scan at 20 weeks GA and delivery reports. Periconceptional was
defined as the period of 4 weeks before until 8 weeks after conception. Timing of initiation of
folic acid use was defined as the initiation at any time before (pre) or after (post) conception of
(multi)vitamin supplements containing folic acid either the standard low dosage of 0.4–0.5
mg/day or high dosage of 5mg/day. Timing of folic acid initiation served as measure for dura-
tion of folic acid supplement use and implicitly the folate status during the first trimester of
pregnancy. In a small subgroup (n = 57) a venous blood sample was collected at enrolment for
determination of red blood cell folate according to the study protocol representing maternal
folate status of 2–4 months previously [29]. Thereby red blood cell folate reflects the folate sta-
tus of the periconceptional period and specifically the preconceptional period. As red blood
cell folate is significantly higher in preconceptional folic acid users (p<0.01), we demonstrated
that red blood cell folate concentration is an accurate indicator of the timing of initiation and
duration of folic acid supplement use in our study population.
High resolution transvaginal three-dimensional ultrasounds were performed weekly
between 6+0 weeks and 12+6 weeks of gestation using a 4.5–11.9 MHz transvaginal probe of a
Voluson E8 system (GE Medical Systems, Zipf, Austria). Series of three-dimensional ultra-
sound sweeps were obtained for biometry measurements focusing on the whole embryo or the
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head separately. Scans were evaluated off-line using specialised 3D-software (4D View, version
7.0, GE Medical Systems). Only high quality images of the fossa posterior in which the cerebel-
lum could be clearly demarcated were accepted for further analysis. We selected only three-
dimensional ultrasound scans between 8+0 weeks and 12+6 weeks gestation, as success rates of
cerebellar measurements before 8 weeks GA were very low [6]. Three-dimensional ultrasound
scans were displayed in the orthogonal multiplanar mode in a standardized format ensuring
that the left and right side corresponded to the viewer’s perspective (Fig 1). Cerebellar measure-
ments were performed in a coronal section of the head at the level of the rhombencephalon
enabling the visualisation of cerebellum, fourth ventricle and choroid plexus of the fourth ven-
tricle as previously described [6]. In order to obtain a clearly defined image of the cerebellum at
12 weeks GA, the coronal plane was rotated slightly over the x-axis. The following cerebellar
measurements were performed: Transcerebellar diameter (TCD) and left and right cerebellar
diameters (LCD, RCD). The ‘distance two points’ function was used to measure the greatest
diameter. All measurements were repeated three times in all eligible 3D sweeps, the mean of
these measurements was used for analyses. The proportional cerebellar growth was calculated
for all cerebellar parameters by dividing the parameter by CRL.
Two observers (IG and AG) measured the cerebellar parameters in the dataset conducted
between 2009 and 2010. Inter-observer reliability and agreement were calculated for 35 cerebel-
lar measurements on randomly selected 3D volumes independently repeated by both measur-
ers. Intra-observer reliability and agreement was evaluated by repeating measurements in 30
randomly selected volumes. Reliability calculations included measurements from all gestational
ages, with a minimum of 5 scans per gestational week. The observers were blinded to each oth-
er’s and previous results.
Fig 1. Protocolled display of the three-dimensional ultrasound scan. Three-dimensional ultrasound image of an embryo at 9+2 weeks GA with the
standardized cerebellum measurements TCD (1), LCD (2), RCD (3) in 4D view.
doi:10.1371/journal.pone.0141089.g001
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Statistical analysis
Statistical analysis was performed using SPSS software version 21.0 (SPSS for Windows, SPSS
Inc., Chicago, Illinois, USA) and SAS software version 9.3 (SAS Institute Inc., Cary, NC, USA).
Results with p-values of 0.05 or lower were considered statistically significant. General charac-
teristics were calculated for all pregnancies and compared between preconceptional and post-
conceptional folic acid supplement users. Continuous data of maternal age, BMI, birth weight
and GA at birth were compared using the MannWhitney U-test. Categorical data of ethnicity,
education, primigravida, nulliparous, mode of conception, periconceptional use of tobacco and
alcohol and infant gender were compared using the Pearson Chi-square test.
To assess the association between timing of initiation of folic acid supplement use during
the periconceptional period and first trimester cerebellar growth trajectories we performed lin-
ear mixed model analyses. The linear mixed model takes into account the existing correlation
between the measurements within one pregnancy. Interaction terms of the timing of initiation
of folic acid supplement use with potential confounders were studied, but not included in the
model as they yielded no significant contribution. A random intercept only was used to model
the within subject correlation, a random slope did not improve the model fit. An unadjusted
mixed model was estimated using TCD, LCD and RCD measurements as response variables
and CRL and GA as predictors. Timing of initiation of folic acid supplement use was used as
independent predictor for cerebellar growth. For the adjusted model we used maternal age,
mode of conception, parity, preconceptional smoking, periconceptional alcohol use, BMI, eth-
nicity, and the measurer as potential confounders, based on literature and significant differ-
ences between the preconceptional and postconceptional user groups [13,30]. Stepwise
backwards elimination of variables with p>0.20 was conducted to determine the final model.
Additionally, quartiles of red blood cell folate were calculated and used to perform linear
mixed models investigating the association with cerebellar growth trajectories. Including the
interaction term between red blood cell folate and GA we were able to study the slope between
the four quartiles using the third quartile (Q3) as reference [12].
Results
In 2009 and 2010, 259 viable singleton pregnancies were eligible for this study. We excluded 2
pregnancies conceived from oocyte donations, 43 miscarriages, 1 ectopic pregnancy, 12 preg-
nancies dated by CRL, 8 pregnancies with abnormal foetal outcome and 7 pregnancies with
missing data. This resulted in a final evaluation of 186 pregnancies of 186 women. In 135
(73%) of all pregnancies scans were eligible for cerebellar measurements. All 135 women
started folic acid supplements before or after conception. Only 7 women were administered
folic acid in a high dosage of 5mg/day, 4 in the preconceptional users and 3 in the post concep-
tion users.
In Table 1 the baseline characteristics of the total group of pregnancies, pregnancies with
measurements, and the groups of preconceptional and postconceptional initiation of folic acid
supplement use are depicted. No significant differences were found between pregnancies with
and without cerebellar measurements, except for BMI. Comparing preconceptional and post-
conceptional folic acid users, general characteristics showed significant differences in ethnicity,
primigravida, nulliparous, periconceptional alcohol use, periconceptional smoking and mode
of conception via IVF/ISCI procedures. Red blood cell folate is significantly higher in the pre-
conceptional folic acid user group (p<0.01). Education level, BMI, neonatal birth weight, GA
at birth and gender were comparable between both groups.
A total number of 880 three-dimensional ultrasounds between 8+0 weeks and 12+6 weeks
gestation were available for detailed cerebellar measurements. The number of measurements
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per pregnancy is shown in table 2. Cerebellar measurements could be performed in 263 vol-
umes, demonstrating an overall success rate of 29.9%, with the highest success rate of 41.0% in
gestational week 8. Table 3 shows the mean of all measurements per gestational week with the
corresponding SD values, and the success rate per gestational week.
Intra-observer reliability analysis showed no significant differences in the mean cerebellar
parameters (TCD = 0.020mm, 95%CI = -0.054 to 0.094, LCD = 0.007mm, 95%CI = -0.043 to
0.057, RCD = 0.030mm, 95%CI = -0.027 to 0.087). ICC values for all parameters were above
0.99, representing an excellent reliability between measurements. Analysis of the inter-observer
agreement showed a significant mean difference between the two measurers (TCD = 0.501mm,
95%CI = 0.260 to 0.742, LCD = 0.310mm 95%CI = 0.134 to 0.485, RCD = 0.200mm 95%
CI = 0.063 to 0.337). A good reliability was established with ICC for TCD, LCD and RCD of
respectively 0.92, 0.84, 0.89.




measurements (n = 135)
Preconceptional Folic acid
users (n = 108)
Postconceptional Folic acid
users (n = 27)
Maternal
Age, years 32.1 (18.9–42.7) 32.1 (18.9–42.3)1 32.1 (20.3–42.1) 32.7 (18.9–42.3)
Ethnicity
Dutch 144 (77.8) 99 (73.3)2 84 (77.8) 15 (55.5)*
Western-other 16 (8.6) 14 (10.4) 11 (10.2) 3 (11.1)
Non-western 25 (13.5) 20 (14.8) 11 (10.2) 9 (33.3)
Education
Low 15 (8.5) 12 (8.9)3 10 (9.3) 2 (7.4)
Intermediate 54 (30.5) 40 (29.6) 31 (28.7) 9 (33.3)
High 108 (61.0) 77 (57.0) 63 (58.3) 14 (51.9)
BMI, kg/m2 23.8 (18.6–38.3) 23.5 (18.6–34.9)** 23.2 (18.6–34.9) 24.1 (19.1–28.7)
Primigravida 69 (37.1) 48 (35.6) 45 (41.7) 3 (11.1)**
Nulliparous 119 (64.0) 83 (61.5) 73 (67.6) 10 (37.0)**
Periconceptional use of
alcohol
85 (45.7) 67 (49.6) 49 (45.4) 18 (66.6)*
Periconceptional
smoking
31 (16.7) 24 (17.8) 14 (12.9) 10 (37.0)**
Red blood cell folate,
nmol/L
1500 (814–2936) 1537 (814–2936) 1626 (844–2936) 1063 (814–1815) **
Mode of Conception IVF/
ICSI
57 (30.6) 40 (29.6) 40 (37.0) 0 (0)**
New-born outcome
Birth weight, grams 3378 (450–4700) 3430 (1715–4700) 3410 (1715–4700) 3440 (2150–4110)
Gestational age at birth,
days
276 (187–294) 276 (228–294) 277 (228–294) 276 (258–291)
Gender, male 88 (47.3) 62 (45.9) 50 (46.3) 12 (44.4)
Continuous data is presented as median, range, categorical data as n (%). BMI, body mass index; IVF/ICSI, in vitro fertilization with or without intra-
cytoplasmic sperm injection; Missing data was due to incomplete questionnaires. Missing
1 n = 3
2 n = 2
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Table 4 depicts the results of both crude and adjusted linear mixed model analyses for all 3
cerebellar diameters and the proportional cerebellar growth trajectories by the timing of initia-
tion of folic acid supplement use. Maternal age, mode of conception, periconceptional smok-
ing, periconceptional alcohol use, ethnicity and the measurer were designated confounders in
the final model. Subsequently, models for TCD, LCD, RCD and proportional growth (cerebel-
lar diameters divided by CRL) were all adjusted for these final confounders. Both crude and
adjusted linear mixed models showed small but significant effects on cerebellar size and pro-
portional cerebellar growth by the timing of initiation of folic acid supplement use as function
of CRL Repeating the same analysis for all cerebellar diameters and the timing of folic acid sup-
plement use initiation as a function of GA, no significant differences were observed in either
crude or adjusted models. Both crude and adjusted models showed significantly increased pro-
portional cerebellar growth for all three cerebellar diameters when folic acid supplement use
was initiated preconceptionally.
In Fig 2 we graphically display the results of the adjusted linear mixed models as regression
lines. The coloured area represents the ninety-five percent prediction interval for both lines.
Comparable results for the right and left cerebellar hemisphere were depicted; therefore we
only display the TCD and RCD graphs. There is a clear linear display of data points showing
slightly increased cerebellar diameters as a function of CRL for TCD (A) and RCD (B). The lin-
ear functions of preconceptional and postconceptional initiation of folic acid supplement use
as function of GA cross for both the total (C) and unilateral (D) cerebellar diameters. Fig 2E
Table 2. 3D-Ultrasound data and the success rate of measurements.
TCD RCD LCD
Images 880 880 880
Measurements 263 (29.9) 259 (29.4) 259 (29.4)
Pregnancies with measurements 135 135 135
 2 measurements 77 (57.1) 75 (55.6) 75 (55.6)
1 measurement 58 (42.9) 60 (44.4) 60 (44.4)
2 measurements 37 (27.4) 36 (26.7) 36 (26.7)
3 measurements 31 (22.9) 31 (22.9) 31 (22.9)
4 measurements 7 (5.1) 6 (4.4) 6 (4.4)
5 measurements 2 (1.5) 2 (1.5) 2 (1.5)
Presented is the number of images (%) eligible for measurement per pregnancy.
TCD, transcerebellar diameter; LCD, left cerebellar diameter; RCD, right cerebellar diameter.
doi:10.1371/journal.pone.0141089.t002
Table 3. Measurements per gestational week, with corresponding mean and SD values.
Ultrasound characteristics Number of measurements CRL, mm TCD, mm RCD, mm LCD, mm
GA 8 weeks 73/178 (41%) 18.65 (3.44) 4.38 (0.74) 2.58 (0.35) 2.58 (0.35)
GA 9 weeks 70/177 (40%) 26.15 (4.50) 5.56 (0.97) 3.06 (0.43) 3.07 (0.47)
GA 10 weeks 44/178 (25%) 36.45 (5.82) 7.18 (1.17) 3.78 (0.56) 3.79 (0.54)
GA 11 weeks 39/181 (22%) 48.43 (6.70) 8.97 (1.03) 4.62 (0.48) 4.61 (0.57)
GA 12 weeks 37/166 (22%) 61.46 (6.95) 10.34 (1.16) 5.20 (0.57) 5.21 (0.58)
Presented are the number of images eligible for analysis relative to the total number and the cerebellar parameters per GA. CRL, crown-rump length;
TCD, transcerebellar diameter; LCD, left cerebellar diameter; RCD, right cerebellar diameter; GA, gestational age.
doi:10.1371/journal.pone.0141089.t003
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and 2F show the proportional growth trajectories as function of GA, with the associated predic-
tion interval, which decreases with advancing gestation.
In our subgroup of 57 patients quartiles for red blood cell folate were calculated (Q1: 814–
1242nmol/L, Q2: 1243–1537nmol/L, Q3: 1538–1813nmol/L and Q4: 1814–2936nmol/L). Lin-
ear mixed models showed the highest cerebellar growth throughout all models of total, left and
right cerebellar diameter in the third quartile of red blood cell folate levels compared to lowest
first and second and highest fourth quartiles as a function of GA (Q1 = -0.0721mm/day, 95%
CI = -0.119 to -0.0250, p< 0.01; Q2 = -0.0438 mm/day, 95%CI = -0.0865 to -0.0011, p< 0.01;
Q4 = -0.0459 mm/day, 95%CI = -0.0927 to 0.0010, p = 0.05) and CRL (Q1 = -0.0364mm/mm,
95%CI = -0681 to -0.0047, p< 0.05; Q2 = -0.0280mm/mm, 95%CI = -0.0568 to 0.0008, p>
0.05; Q4 = -0.0232mm/mm, 95%CI = -0.0554 to 0.0089, p> 0.05). The same accounts for
proportional cerebellar growth which was the highest in Q3 (Q1 = -0.0017mm/mm/day, 95%
CI = -0.0039 to 0.0001, p>0.05; Q2 = -0.0010mm/mm/day, 95%CI = -0.0026 to 0.0006,
p>0.05; Q4 = -0.0459 mm/day, 95%CI = -0.0018 to -0.0001, p< 0.05). Fig 3 depicts cerebellar
growth trajectories associated with the four quartiles of maternal red blood cell folate levels.
Discussion
This study shows increased, albeit slightly, embryonic cerebellar diameters and proportional
cerebellar growth trajectories in ongoing non-malformed pregnancies in a tertiary hospital
Table 4. Preconceptional compared to postconceptional initiation of folic acid supplement use and
embryonic cerebellar size and growth trajectories as function of gestational age and crown-rump
length.
Model β (se) 95% CI p-value
TCD vs. CRL Crude 0.286 (0.098) 0.090; 0.482 0.005
Adjusted 0.257 (0.117) 0.023; 0.491 0.032
LCD vs. CRL Crude 0.153 (0.057) 0.038; 0.268 0.010
Adjusted 0.171 (0.067) 0.038; 0.305 0.013
RCD vs. CRL Crude 0.132 (0.054) 0.024; 0.240 0.018
Adjusted 0.156 (0.062) 0.032; 0.280 0.015
TCD vs. GA Crude 0.112 (0.142) -0.174; 0.398 0.436
Adjusted -0.078 (0.154) -0.388; 0.232 0.616
LCD vs. GA Crude 0.093 (0.069) -0.045; 0.232 0.183
Adjusted 0.041 (0.078) -0.115; 0.197 0.601
RCD vs. GA Crude 0.048 (0.068) -0.090; 0.185 0.490
Adjusted 0.008 (0.076) -0.144; 0.159 0.918
TCD/CRL ratio vs. GA Crude 0.015 (0.004) 0,007; 0,024 0.001
Adjusted 0.015 (0.005) 0.005; 0.024 0.003
LCD/CRL ratio vs. GA Crude 0.010 (0.003) 0.004; 0.016 0.002
Adjusted 0.012 (0.003) 0.005; 0.018 0.001
RCD/CRL ratio vs. GA Crude 0.010 (0.003) 0.004; 0.015 0.001
Adjusted 0.011 (0.003) 0.005; 0.017 0.001
Crude and adjusted linear mixed models comparing effect estimates of preconceptional with
postconceptional folic acid use of cerebellar growth trajectories. Estimates are depicted as embryonic
cerebellar measurement (TCD, LCD and RCD) in mm per mm increase in CRL or days increase in GA.
Crude model: Unadjusted model. Adjusted model, adjusted for designated confounders after stepwise
backward elimination. TCD, transcerebellar diameter; LCD, left cerebellar diameter; RCD, right cerebellar
diameter; CRL, crown-rump length; GA, gestational age; CI, conﬁdence interval.
doi:10.1371/journal.pone.0141089.t004
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Fig 2. Longitudinal cerebellar measurements and proportional growth by folic acid initiation. Adjusted linear mixed models representing the effects of
preconceptional compared to postconceptional initiation of folic acid supplement use on cerebellar size and growth trajectories as function of CRL in
millimetres (A and B) and GA in days (C and D) and proportional cerebellar growth trajectories (E and F).
doi:10.1371/journal.pone.0141089.g002
Fig 3. Associations between periconceptional red blood cell folate quartiles and cerebellar growth trajectories. Linear mixed models representing
the effects of red blood cell folate quartiles on cerebellar growth trajectories as a function of CRL in millimetres and GA in days. The blue line represents the
third quartile used as reference.
doi:10.1371/journal.pone.0141089.g003
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setting when maternal folic acid supplement use was initiated before conception compared to
post conception. Hereby, we discriminate between overall embryonic growth and embryonic
cerebellar growth. This data are validated in a subgroup by maternal red blood cell folate levels
before 8 weeks GA which is a more reliable marker for periconceptional folate status. It is
intriguing that the third quartile of red blood cell folate levels (1538–1813 nmol/L) seems to be
the optimum for embryonic cerebellar growth of which the implications for fetal cerebellar
growth and future neurodevelopmental outcome needs further investigation. This first study
investigating associations between periconceptional folate status and human embryonic cere-
bellar size and growth trajectories may substantiate to previous animal studies showing alter-
ations in cerebellar growth and development in a folic acid deficient environment [27,31,32].
Besides, our results are in agreement with previous human studies demonstrating significant
positive effects of periconceptional maternal folic acid supplement use and folate status on
embryonic and fetal size [12,20,30] and DNAmethylation of the growth gene IGF2 DMR
[33,34].
By establishing a prospective dataset of serial first trimester three-dimensional ultrasound
images together with periconceptional exposure data and follow-up information, we were able
to study associations between periconceptional folic acid supplement use and embryonic cere-
bellar growth. We substantiate the validity of our questionnaire data by verification at the
intake visit and measurements of red blood cell folate concentrations in a subgroup. Although
data on the precise day of folic acid initiation was not available, red blood cell folate levels were
significantly higher when the timing of initiation of folic acid supplement use was defined as
preconceptional. This agrees with the assumption that the timing of folic acid use initiation
serves as measure for periconceptional folate status which may involve the embryonic environ-
ment as well. First trimester red blood cell folate levels follow an optimum curve in which the
third quartile is associated with the highest cerebellar growth rates compared to the first two
and upper quartile which corresponds to the available evidence of its effects on overall embry-
onic growth [12]. Because of the prospective and observational character of our study we were
able to study associations, causality however could not be shown, since this warrants a rando-
mised controlled trial.
The low success rates of the cerebellar measurements are comparable to previous publica-
tions and are due to non-targeted scanning for the purpose of embryonic biometry and volu-
metric measurements, motion artefacts, acoustic shadowing and maternal factors, such as BMI
and an unfavourable position of the uterus [6]. Although differential confounding may be an
issue, it seems unlikely as these factors are unrelated to the selected population, the timing of
folic acid initiation, red blood cell folate levels and cerebellar outcome. Low success rates could
compromise the longitudinal setting of the study. Yet, 57% of the patients had 2 or more mea-
surements. Since measurements within subjects are strongly correlated, linear mixed models
are the most appropriate method for the statistical analyses of our data. Preconceptional and
postconceptional folic acid users are in many ways not totally comparable. Hence, for statistical
analyses we adjusted for known confounders of embryonic growth and maternal characteristics
to minimize confounding. Demonstrating comparable effects in both crude and adjusted mod-
els for all cerebellar diameters strengthened the model fit.
Differences in cerebellar size and proportional growth trajectories may be explained biologi-
cally by folates’ vital role in synthesis of DNA, RNA and proteins for cellular growth and differ-
entiation processes. It could be hypothesized that in early embryonic development epigenetic
modification of genes including those regulating the development of the cerebellum as part of
the central nervous system is altered by the use of folic acid amongst other factors [34,35].
Also, the proportion of cerebellar size in relation to CRL increased when folic acid use was ini-
tiated before conception. This is either the result of a larger cerebellum, a smaller CRL, or a
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combination of the two. Since previous literature demonstrated larger embryonic and fetal bio-
metric measurements in association with optimal folate status, proportional cerebellar growth
seems to be increased due to a relatively larger cerebellum in particular [12,30]. However we
did not find significant differences in cerebellar measurements between preconceptional and
postconceptional folic acid users using GA as predictor. We assume that this is the result of
inaccurate pregnancy dating, despite using strict criteria based on reliable LMP only. Inaccu-
rate determination of GA is a recurrent issue in embryonic and foetal growth studies [30]. In
this context, it is important to consider that our methodology for pregnancy dating is stricter
than methods used routinely for clinical practice. Hence, our method enables designation of
very early growth deviations corrected by pregnancy dating using CRL.
Prenatal modification of cerebellar growth potentially has consequences for neurodevelop-
mental outcome [14,15]. One could speculate that early changes in embryonic size affect neu-
rodevelopmental functions in early and later life. However, exploring the association between
the small differences of embryonic cerebellar growth and its possible clinical implications is
beyond the scope of this study. This warrants larger periconceptional cohorts including bio-
markers and pre- and postnatal neuroimaging combined with long term standardized neuro-
developmental follow-up. Also, considering the tertiary hospital setting, external validity of our
results should be studied in a general population cohort.
In conclusion, our findings show small albeit significant associations between preconcep-
tional initiation compared to postconceptional initiation of folic acid supplement use, used as
measure of folate status in the embryonic environment, and increased size and growth trajecto-
ries of the embryonic cerebellum. Although the effects of these small differences for prenatal
and postnatal neurodevelopment are unknown, this study further supports the importance of
periconceptional maternal folic acid supplement use.
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